Clinical Trials and the Future of Lymphoma Treatment

Current lymphoma therapies are a far cry from the mustard gas used more than 50 years ago. More treatment options, including ones that may be more effective and less toxic, are being studied in ongoing clinical trials.

“Clinical trials really are the future of lymphoma treatment,” says Ann LaCasce, MD, a medical oncologist in the Adult Lymphoma Program at Dana-Farber/Brigham and Women’s Cancer Center.

Ann LaCasce, MD

Ann LaCasce, MD

Clinical trials have led to a number of improved therapies for both Hodgkin and non-Hodgkin lymphomas, including approved drugs like BrentuximabIbrutinib and Lenalidomide. Meanwhile, studies continue on other promising new drugs like Idelalisib.

LaCasce details many of these new drugs and future treatment options in her presentation, “Clinical Trials, Emerging New Drugs and Future Concepts of Treatment in Lymphoma.” The talk was given at the Lymphoma Research Foundation’s (LRF) North American Educational Forum in September 2013.

To view LaCasce’s presentation, visit the Dana-Farber Slideshare page.

View more presentations given at the LRF’s annual conference:

Comments Sort By Newest

One thought on “Clinical Trials and the Future of Lymphoma Treatment

  1. Dr. Ann, your comments about “mustard gas” are particularly timely considering some of the popular chatter about Bendamustine, essentially an old chemotherapy. I’m no expert, just one DFCI patient who has participated in a few Clinical Trials of emerging targeted therapies which I believe will prove to be safer and more effective than conventional chemotherapy. Just my opinion- cancer patients should engage his/her oncologist to explore what novel treatment options are available in Clinical Trials. As we travel the road to Personalized Medicine still under construction, genomics-based therapy rather than empirical therapy might be our best option. Jack

  2. Dr. Ann, your comments about “mustard gas” are particularly timely considering some of the popular chatter about Bendamustine, essentially an old chemotherapy. I’m no expert, just one DFCI patient who has participated in a few Clinical Trials of emerging targeted therapies which I believe will prove to be safer and more effective than conventional chemotherapy. Just my opinion- cancer patients should engage his/her oncologist to explore what novel treatment options are available in Clinical Trials. As we travel the road to Personalized Medicine still under construction, genomics-based therapy rather than empirical therapy might be our best option. Jack

Comments are closed.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

Latest Tweets

Dana-Farber @danafarber
As recently as up to 10 years ago, #ovariancancer patients had fewer options for treatment. Targeted therapies have… https://t.co/tPLFcyIwpN
Dana-Farber @danafarber
When bone marrow can no longer keep up with the body's needs for new blood cells, it can lead to serious consequenc… https://t.co/gMhLId8U0y
Dana-Farber @danafarber
Itchy skin has many causes, including dryness & allergies, but only rarely does it signal that a person has cancer:… https://t.co/jZfr7PbBfq

Patient and Family Blogs

Patients and families of patients at Dana-Farber often chronicle their own experiences with cancer.

Here are some blogs that you can follow.